XOLREMDI
Growthmavorixafor
NDAORALCAPSULEPriority Review
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
7
Data completeness
4/8 — Partial
Priority Review
XOLREMDI (mavorixafor) is cxc chemokine receptor 4 antagonists [moa]. First approved in 2024.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XOLREMDI (mavorixafor) is an oral small-molecule CXC chemokine receptor 4 (CXCR4) antagonist approved in April 2024. It modulates immune cell mobilization by blocking CXCR4 signaling, enabling mobilization of hematopoietic stem cells and other immune populations. The mechanism supports treatment of conditions characterized by abnormal immune cell trafficking or mobilization deficiency.
Growth12.4 years to LOE
Early-stage growth product with minimal competitive pressure presents opportunity for team expansion and market-building roles in a nascent franchise.
Mechanism of Action
CXC Chemokine Receptor 4 Antagonists
Pharmacologic Class:
CXC Chemokine Receptor 4 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
Started Feb 2025
48 enrolled
Hepatic Insufficiency
Drug-Drug Interaction Potential of Mavorixafor
Started Feb 2025
38 enrolled
Healthy Participants
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Started Jun 2024
176 enrolled
Neutropenia
A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders
Started Oct 2021
32 enrolled
Neutropenia
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
Started Apr 2020
16 enrolled
Waldenstrom's Macroglobulinemia
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.